These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 25017046)

  • 1. Back-up strategies in drug discovery: what, how and when?
    Provins L; Jnoff E; Genicot C
    Drug Discov Today; 2014 Nov; 19(11):1808-1811. PubMed ID: 25017046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decision-making in product portfolios of pharmaceutical research and development--managing streams of innovation in highly regulated markets.
    Jekunen A
    Drug Des Devel Ther; 2014; 8():2009-16. PubMed ID: 25364229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decision making in surgical treatment of chronic low back pain: the performance of prognostic tests to select patients for lumbar spinal fusion.
    Willems P
    Acta Orthop Suppl; 2013 Feb; 84(349):1-35. PubMed ID: 23427903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mathematical model for maximizing the value of phase 3 drug development portfolios incorporating budget constraints and risk.
    Patel NR; Ankolekar S; Antonijevic Z; Rajicic N
    Stat Med; 2013 May; 32(10):1763-77. PubMed ID: 23300097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.
    Betz UA
    Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated project views: decision support platform for drug discovery project teams.
    Baede EJ; den Bekker E; Boiten JW; Cronin D; van Gammeren R; de Vlieg J
    J Chem Inf Model; 2012 Jun; 52(6):1438-49. PubMed ID: 22640375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resource allocation within the National AIDS Control Program of Pakistan: a qualitative assessment of decision maker's opinions.
    Husain S; Kadir M; Fatmi Z
    BMC Health Serv Res; 2007 Jan; 7():11. PubMed ID: 17244371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translational strategies for development of monoclonal antibodies from discovery to the clinic.
    Tabrizi MA; Bornstein GG; Klakamp SL; Drake A; Knight R; Roskos L
    Drug Discov Today; 2009 Mar; 14(5-6):298-305. PubMed ID: 19152840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making.
    Dambach DM; Misner D; Brock M; Fullerton A; Proctor W; Maher J; Lee D; Ford K; Diaz D
    Chem Res Toxicol; 2016 Apr; 29(4):452-72. PubMed ID: 26625186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collaborative virtual organisation and infrastructure for drug discovery.
    Hardy B; Affentranger R
    Drug Discov Today; 2013 Jul; 18(13-14):681-6. PubMed ID: 23416145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of translational bioinformatics in drug discovery.
    Buchan NS; Rajpal DK; Webster Y; Alatorre C; Gudivada RC; Zheng C; Sanseau P; Koehler J
    Drug Discov Today; 2011 May; 16(9-10):426-34. PubMed ID: 21402166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risks of subconscious biases in drug-discovery decision making.
    Segall M; Chadwick A
    Future Med Chem; 2011 May; 3(7):771-4. PubMed ID: 21644820
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful healthcare programs and projects: organization portfolio management essentials.
    Pickens S; Solak J
    J Healthc Inf Manag; 2005; 19(1):19-27. PubMed ID: 15682672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing quality decision-making: regulatory and pharmaceutical industry perspectives.
    Donelan R; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):319-28. PubMed ID: 25628072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of ion channel targets.
    Gerlach AC; Antonio BM
    Channels (Austin); 2015; 9(6):376-9. PubMed ID: 26556675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Public-Private Partnerships in Lead Discovery: Overview and Case Studies.
    Gottwald M; Becker A; Bahr I; Mueller-Fahrnow A
    Arch Pharm (Weinheim); 2016 Sep; 349(9):692-7. PubMed ID: 27335205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative Systems Pharmacology: A Case for Disease Models.
    Musante CJ; Ramanujan S; Schmidt BJ; Ghobrial OG; Lu J; Heatherington AC
    Clin Pharmacol Ther; 2017 Jan; 101(1):24-27. PubMed ID: 27709613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INTEGRATING HEALTH TECHNOLOGY ASSESSMENT PRINCIPLES IN FORMULARY MANAGEMENT.
    Teng M; Khoo AL; Zhao YJ; Lin L; Lim BP
    Int J Technol Assess Health Care; 2016 Jan; 32(1-2):81-7. PubMed ID: 27001376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An unbalanced portfolio.
    Federsel HJ
    Drug News Perspect; 2009 Jun; 22(5):287-92. PubMed ID: 19609466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.